It's been less than a week since Mylan completed its deal with Abbott, scooping up a large chunk of the Illinois company's overseas generics business. But CEO Heather Bresch is already hinting at another big transaction.
Canon U.S.A. has established a subsidiary company devoted to its global biomedical business, Canon BioMedical. It's not the only camera company looking to med tech to fuel future growth; last week Nikon bought Optos for $400 million in a bid to establish its first outpost in the medical industry.
During the continued wave of life science M&A, companies are seeking to focus on core competencies. Once again, this trend has resulted in Boston Scientific snatching the medical device assets of a pharma company, this time from Endo International.
A Teva plant in Pennsylvania and hundreds of jobs have been spared the ax that the Israeli company has been swinging left and right as it cuts costs in the face of patent cliff issues. Instead, a family-owned business from New Jersey will acquire the Sellersville facility along with about two dozen drugs that are manufactured there.
GlaxoSmithKline and Novartis have finally closed the multibillion-dollar asset swap that's sending GSK's oncology portfolio to Switzerland in exchange for most of the latter's vaccines unit. Now, all eyes will be on the British pharma giant, who industry watchers agree has more to prove after exiting the fast-growing cancer field.
Novartis has been rubbing its hands together in anticipation of taking over GlaxoSmithKline's cancer portfolio. Now it can. The two drug giants wrapped up their big sale-and-swap, putting Novartis in charge of GSK oncology meds, from Arzerra to Votrient.
After months of speculation, Johnson & Johnson, the world's biggest maker of healthcare products, put the rumors to rest by confirming the sale of its Cordis vascular device unit to Cardinal Health for $1.9 billion. The deal is expected to be completed by the end of the year.
Nikon will acquire the Optos Group for £259.3 million ($400 million) as part of its long-term plan to expand into the medical sector. Last June, the long-suffering camera giant restructured and unveiled a plan to establish itself again as a growth company--part of that is to leverage its optical technologies to expand into the medical industry.
Neuromodulation company Cyberonics and cardiovascular device player Sorin in an all-stock deal that now values the combination at $3 billion.
So far, the 2014 pharma deal blitz has continued right on into 2015. And cancer drugmaker Pharmacyclics could be the next company to keep it going.